Ppreferentially expressed antigen in melanoma (PRAME) t cell receptors and methods of use thereof
MYPI2025005476A0Undetermined Publication Date: 2021-07-24REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025005476
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-01-24
- Filing Date
- 2021-01-22
- Publication Date
- 2021-07-24
Abstract
The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs. No suitable figure.
Need to check novelty before this filing date? Find Prior Art
